Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Dec 8;82(1):151–156. doi: 10.1054/bjoc.1999.0892

Screening for BRCA2 mutations in 81 Dutch breast–ovarian cancer families

T Peelen 1, M van Vliet 1,6, A Bosch 1, G Bignell 4, H F A Vasen 3, J G M Klijn 5, H Meijers-Heijboer 6, M Stratton 4, G-J B van Ommen 1, C J Cornelisse 2, P Devilee 1,2
PMCID: PMC2363204  PMID: 10638982

Abstract

We have analysed 81 families with a history of breast and/or ovarian cancer for the presence of germline mutations in BRCA2 with a number of different mutation screening techniques. The protein truncation test (PTT) for exons 10 and 11 detected four different frame-shifting mutations in six of these families. Four of the remaining 75 families had given positive linkage evidence for being due to BRCA2. In these families the entire coding region was analysed by single-strand conformational polymorphism, leading to the detection of a non-sense and a splice-site mutation in two of them. While these studies were in progress, Southern analysis of BRCA1 revealed that in our study-population of 81 families, 15 families were segregating either the exon 13 or exon 22 deletion in BRCA1 (Petrij-Bosch et al (1997) Nat Genet17: 341–345). This prompted us to examine BRCA2 in the remaining 58 families by Southern analysis, using two different restriction enzymes. No aberrations were found in the restriction patterns. Thus, contrary to BRCA1, large genomic rearrangements within the BRCA2 gene do not represent a major mutation mechanism among Dutch breast cancer families. © 2000 Cancer Research Campaign

Keywords: BRCA1, BRCA2, mutation analysis, breast cancer

Full Text

The Full Text of this article is available as a PDF (145.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cornelis R. S., Vasen H. F., Meijers-Heijboer H., Ford D., van Vliet M., van Tilborg A. A., Cleton F. J., Klijn J. G., Menko F. H., Meera Khan P. Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer. Hum Genet. 1995 May;95(5):539–544. doi: 10.1007/BF00223866. [DOI] [PubMed] [Google Scholar]
  2. Ford D., Easton D. F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D. T., Weber B., Lenoir G., Chang-Claude J. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998 Mar;62(3):676–689. doi: 10.1086/301749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gayther S. A., Mangion J., Russell P., Seal S., Barfoot R., Ponder B. A., Stratton M. R., Easton D. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997 Jan;15(1):103–105. doi: 10.1038/ng0197-103. [DOI] [PubMed] [Google Scholar]
  4. Hogervorst F. B., Cornelis R. S., Bout M., van Vliet M., Oosterwijk J. C., Olmer R., Bakker B., Klijn J. G., Vasen H. F., Meijers-Heijboer H. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet. 1995 Jun;10(2):208–212. doi: 10.1038/ng0695-208. [DOI] [PubMed] [Google Scholar]
  5. Lancaster J. M., Wooster R., Mangion J., Phelan C. M., Cochran C., Gumbs C., Seal S., Barfoot R., Collins N., Bignell G. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet. 1996 Jun;13(2):238–240. doi: 10.1038/ng0696-238. [DOI] [PubMed] [Google Scholar]
  6. Miki Y., Katagiri T., Kasumi F., Yoshimoto T., Nakamura Y. Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet. 1996 Jun;13(2):245–247. doi: 10.1038/ng0696-245. [DOI] [PubMed] [Google Scholar]
  7. Miller S. A., Dykes D. D., Polesky H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988 Feb 11;16(3):1215–1215. doi: 10.1093/nar/16.3.1215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Neuhausen S. L., Godwin A. K., Gershoni-Baruch R., Schubert E., Garber J., Stoppa-Lyonnet D., Olah E., Csokay B., Serova O., Lalloo F. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet. 1998 Jun;62(6):1381–1388. doi: 10.1086/301885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Neuhausen S., Gilewski T., Norton L., Tran T., McGuire P., Swensen J., Hampel H., Borgen P., Brown K., Skolnick M. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet. 1996 May;13(1):126–128. doi: 10.1038/ng0596-126. [DOI] [PubMed] [Google Scholar]
  10. Nordling M., Karlsson P., Wahlström J., Engwall Y., Wallgren A., Martinsson T. A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family. Cancer Res. 1998 Apr 1;58(7):1372–1375. [PubMed] [Google Scholar]
  11. Peelen T., Cornelis R. S., van Vliet M., Petrij-Bosch A., Cleton-Jansen A. M., Meijers-Heijboer H., Klijn J. G., Vasen H. F., Cornelisse C. J., Devilee P. The majority of 22 Dutch high-risk breast cancer families are due to either BRCA1 or BRCA2. Eur J Hum Genet. 1996;4(4):225–230. doi: 10.1159/000472203. [DOI] [PubMed] [Google Scholar]
  12. Peelen T., van Vliet M., Petrij-Bosch A., Mieremet R., Szabo C., van den Ouweland A. M., Hogervorst F., Brohet R., Ligtenberg M. J., Teugels E. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet. 1997 May;60(5):1041–1049. [PMC free article] [PubMed] [Google Scholar]
  13. Petrij-Bosch A., Peelen T., van Vliet M., van Eijk R., Olmer R., Drüsedau M., Hogervorst F. B., Hageman S., Arts P. J., Ligtenberg M. J. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet. 1997 Nov;17(3):341–345. doi: 10.1038/ng1197-341. [DOI] [PubMed] [Google Scholar]
  14. Petrij-Bosch A., Peelen T., van Vliet M., van Eijk R., Olmer R., Drüsedau M., Hogervorst F. B., Hageman S., Arts P. J., Ligtenberg M. J. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet. 1997 Nov;17(3):341–345. doi: 10.1038/ng1197-341. [DOI] [PubMed] [Google Scholar]
  15. Phelan C. M., Lancaster J. M., Tonin P., Gumbs C., Cochran C., Carter R., Ghadirian P., Perret C., Moslehi R., Dion F. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet. 1996 May;13(1):120–122. doi: 10.1038/ng0596-120. [DOI] [PubMed] [Google Scholar]
  16. Puget N., Sinilnikova O. M., Stoppa-Lyonnet D., Audoynaud C., Pagès S., Lynch H. T., Goldgar D., Lenoir G. M., Mazoyer S. An Alu-mediated 6-kb duplication in the BRCA1 gene: a new founder mutation? Am J Hum Genet. 1999 Jan;64(1):300–302. doi: 10.1086/302211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Puget N., Stoppa-Lyonnet D., Sinilnikova O. M., Pagès S., Lynch H. T., Lenoir G. M., Mazoyer S. Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer Res. 1999 Jan 15;59(2):455–461. [PubMed] [Google Scholar]
  18. Puget N., Torchard D., Serova-Sinilnikova O. M., Lynch H. T., Feunteun J., Lenoir G. M., Mazoyer S. A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. Cancer Res. 1997 Mar 1;57(5):828–831. [PubMed] [Google Scholar]
  19. Rahman N., Stratton M. R. The genetics of breast cancer susceptibility. Annu Rev Genet. 1998;32:95–121. doi: 10.1146/annurev.genet.32.1.95. [DOI] [PubMed] [Google Scholar]
  20. Ramus S. J., Kote-Jarai Z., Friedman L. S., van der Looij M., Gayther S. A., Csokay B., Ponder B. A., Olah E. Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer. Am J Hum Genet. 1997 May;60(5):1242–1246. [PMC free article] [PubMed] [Google Scholar]
  21. Serova-Sinilnikova O. M., Boutrand L., Stoppa-Lyonnet D., Bressac-de-Paillerets B., Dubois V., Lasset C., Janin N., Bignon Y. J., Longy M., Maugard C. BRCA2 mutations in hereditary breast and ovarian cancer in France. Am J Hum Genet. 1997 May;60(5):1236–1239. [PMC free article] [PubMed] [Google Scholar]
  22. Smith T. M., Lee M. K., Szabo C. I., Jerome N., McEuen M., Taylor M., Hood L., King M. C. Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Genome Res. 1996 Nov;6(11):1029–1049. doi: 10.1101/gr.6.11.1029. [DOI] [PubMed] [Google Scholar]
  23. Szabo C. I., King M. C. Population genetics of BRCA1 and BRCA2. Am J Hum Genet. 1997 May;60(5):1013–1020. [PMC free article] [PubMed] [Google Scholar]
  24. Thorlacius S., Olafsdottir G., Tryggvadottir L., Neuhausen S., Jonasson J. G., Tavtigian S. V., Tulinius H., Ogmundsdottir H. M., Eyfjörd J. E. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996 May;13(1):117–119. doi: 10.1038/ng0596-117. [DOI] [PubMed] [Google Scholar]
  25. Tonin P. N., Mes-Masson A. M., Futreal P. A., Morgan K., Mahon M., Foulkes W. D., Cole D. E., Provencher D., Ghadirian P., Narod S. A. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet. 1998 Nov;63(5):1341–1351. doi: 10.1086/302099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Vehmanen P., Friedman L. S., Eerola H., Sarantaus L., Pyrhönen S., Ponder B. A., Muhonen T., Nevanlinna H. A low proportion of BRCA2 mutations in Finnish breast cancer families. Am J Hum Genet. 1997 May;60(5):1050–1058. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES